Medline Inc. Reports First Quarter 2026 Results: Strong Sales Growth, Profit Decline, and Raised Guidance

NORTHFIELD, Ill., May 6, 2026 – Medline Inc. (Nasdaq: MDLN), the world’s largest provider of medical-surgical products and supply chain solutions, has released its financial results for the first quarter of 2026. The report shows robust sales momentum, tempered by margin pressures and significant changes in profitability, along with an upgraded outlook for the remainder of the year.

Key Financial Highlights

• Net Sales: \$7.4 billion, a 10.7% increase versus Q1 2025, driven by both new customer implementations and expanded business with existing clients.
• Organic Sales Growth: 10.1% increase, reflecting core operational strength.
• Net Income: \$239 million, down 25.8% from \$322 million in Q1 2025. This decline is mainly attributed to higher costs of goods sold (including tariff impacts), increased operating expenses to support customer growth, and a special IPO-related employee bonus.
• Adjusted EBITDA: \$776 million, a 10.6% decrease year-over-year.
• Diluted EPS: \$0.16; Adjusted Diluted EPS: \$0.33.
• Free Cash Flow: \$316 million, down 45.9% from \$584 million, due to increased working capital needs and continued investment in automation and distribution enhancements.
• Net Leverage: 3.1x (Net Debt of \$10.5 billion; Total Debt \$12.8 billion).

Segment Performance

• Medline Brand Segment:
  • Net sales: \$3.47 billion (+6.2%)
  • Adjusted EBITDA: \$765 million (-7.8%)
  • Adjusted EBITDA Margin: 22.1% (down from 25.4%)
• Supply Chain Solutions Segment:
  • Net sales: \$3.89 billion (+15.0%)
  • Adjusted EBITDA: \$187 million (+2.7%)
  • Adjusted EBITDA Margin: 4.8% (down from 5.4%)

Updated 2026 Guidance

• Organic Sales Growth Guidance Raised: Now targeting 8.5%–9.5% growth for the full year 2026 (up from 8%–9% previously).
• Adjusted EBITDA Guidance Maintained: \$3.5–\$3.6 billion.

Key Factors Affecting Results and Outlook

• Cost Pressures: Margin contraction was driven by higher cost of goods sold (notably tariffs), and increased operating expenses related to onboarding new customers and an IPO-linked employee bonus.
• Operational Investments: Ongoing capital expenditures are being made to further automate and enhance distribution centers and manufacturing facilities.
• Interest Expense: Interest expense declined significantly year-over-year (\$136M in Q1 2026 vs. \$210M in Q1 2025), providing some offset to profit pressures.
• Cash Flow Decline: Free cash flow dropped sharply as working capital requirements rose, primarily due to increased trade accounts receivable and inventory buildup accompanying sales growth.

Other Noteworthy Items for Investors

• IPO-Related Costs: Q1 2026 included \$27 million of expenses tied to the company’s IPO and subsequent offerings, including legal, accounting, advisory fees, and a one-time employee bonus. These costs are non-recurring but affected quarterly profitability.
• Litigation/Non-Core Charges: The quarter included \$8 million in losses on asset disposals and exits, as well as other project costs, foreign exchange impacts, and recoveries related to certain customer receivables.
• Tax Receivable Agreement (TRA) Liability: Increased to \$4.0 billion from \$3.5 billion at year-end 2025.

Balance Sheet Snapshot (as of March 28, 2026)

• Total Assets: \$39.0 billion
• Cash & Equivalents: \$2.24 billion
• Total Debt: \$12.76 billion
• Stockholders’ Equity: \$19.35 billion

Risks and Forward-Looking Statements

Medline’s management highlighted a number of risk factors that could materially impact future results, including:

• Global supply chain disruptions and tariff-related costs
• Healthcare industry consolidation and pricing pressures
• Dependence on major customers and group purchasing organizations
• Potential product recalls, IT/cybersecurity risks, and regulatory compliance challenges
• Macroeconomic and geopolitical uncertainties (including ongoing conflicts in Ukraine and the Middle East)
• Impact of AI and automation on operations and regulatory frameworks
• Substantial indebtedness and financial covenants

Shareholder Implications & Price-Sensitive Items

• Positive: Raised organic sales guidance signals confidence in demand momentum and may be viewed favorably by the market.
• Negative: Significant declines in net income, adjusted EBITDA, and free cash flow, along with margin compression, may pressure the stock, especially if investors focus on profitability over growth.
• Neutral/Watch: IPO and non-recurring costs have impacted Q1 profitability, but are not expected to recur at the same level. Ongoing investments and cost inflation should be closely monitored.

Conference Call and Additional Information

Medline will host a live conference call for investors and analysts on May 6, 2026, at 8:30 a.m. CT / 9:30 a.m. ET. The call will be webcast via the company’s investor relations website (ir.medline.com).

Conclusion

Medline’s Q1 2026 report is a mix of strong sales growth and raised guidance, offset by profit and cash flow declines, and ongoing cost pressures. The upgraded outlook is a positive signal, but investors should be mindful of the margin dynamics, working capital trends, and the company’s ability to convert sales growth into sustainable profit and cash generation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full official filings and consult their financial advisors before making any investment decisions. Financial results and guidance are subject to risks and uncertainties as described in Medline’s forward-looking statements.